Fidelma Russo’s Post

Freenome will present a poster at the Early Detection of Cancer Conference (EDCC) in Portland on Oct. 21. The poster, “Integrated Recruitment Strategies to Enhance Representation in a Large Colorectal Cancer Screening Study,” will be presented by Karolina Kutnik, Senior Clinical Scientist, and shares insights from PREEMPT CRC — the largest prospective study of a blood-based colorectal cancer screening test. The study combined traditional clinical sites with a decentralized clinical trial (DCT) metasite to support recruitment of more than 40,000 participants with broad racial, ethnic, and geographic representation. Co-hosted by the OHSU Knight Cancer Institute, Cancer Research UK (CRUK), and the Canary Center at the Stanford University School of Medicine, EDCC brings together global leaders advancing the science of early cancer detection. #EDCC2025 #ColorectalCancer #ClinicalTrials #EarlyDetection

The Third International Congress of Cancer Sciences (#ICSC 2025) takes place from 7 to 9 October 2025 in Ercolano–Naples, Italy, gathering leading researchers and clinicians to discuss transformative advances in cancer science and therapy. Tomorrow, senior scientist Elisabetta Palamà delivers an invited lecture, presenting advances in in vitro platforms for oncology. Her talk highlights how 3D cancer models and organ-on-chip systems—such as #MIVO—are transforming preclinical research by offering more predictive, human-relevant insights that better align with clinical outcomes. On 9 October, she will also join the “Provocative Lectures and Round Tables” session, contributing to forward-looking discussions on the future of cancer science. ICSC 2025 brings together leading voices in oncology to critically assess emerging paradigms and accelerate the translation of discovery into effective therapies.

Breast Cancer Awareness Month reminds us of the urgent need for continued innovation in cancer research and care. With 1 in 8 women diagnosed with breast cancer in their lifetime, the work happening in labs and research centers around the world has never been more important. Working with life science and biotech companies focused on breast cancer research has given us profound insight into the dedication required to make meaningful progress. Brilliant innovators are developing liquid biopsy assays for earlier detection, creating AI-powered diagnostic tools, and pioneering immunotherapies that leverage the body's own defenses against cancer. What moves us most is witnessing how their scientific breakthroughs translate into real hope for patients and families. Every clinical trial, every FDA approval, and every published study represents years of meticulous work aimed at saving lives. We're deeply honored to help communicate groundbreaking research from partners including Count Me In: Patient-Partnered Research, diagnostic solutions offered by Foresight Diagnostics and SOPHiA GENETICS, and innovative therapies in development at MBrace Therapeutics among many others. #BreastCancerAwarenessMonth #OncologyResearch #BreastCancerInnovation #LifeScience #Biotech #CancerResearch #PrecisionOncology #HealthcareInnovation

Innovative cancer therapies are not just the future—they’re already winning public support. A new survey from Roswell Park Comprehensive Cancer Center shows how popular cutting-edge cellular immunotherapies are, both for their potential to deliver long-term success and their reduced side effects compared with traditional cancer treatments. New York is a major hub for CAR T-cell therapy—from pioneering research to advanced manufacturing and clinical applications. Our state’s world-class academic medical centers and specialized cancer facilities lead the way in bringing these breakthroughs from the lab to the clinic. To keep groundbreaking cures invented, manufactured, and tested right here in New York, we need a statewide biomedical research institute. Want to hear what we’re proposing—and how you can help make it a reality? Sign up: nycures.org

How ecDNA Fuels Tumor Growth and Survival Paul Mischel, a cancer researcher at Stanford, is leading efforts to decode extrachromosomal DNA (ecDNA) in tumors—small, circular DNA that contributes to cancer growth and treatment resistance. Although known for decades, ecDNA gained attention through Mischel's work, which showed its prevalence and adaptability across various cancers. He has formed a global research consortium to explore ecDNA's biology and vulnerabilities. Recent findings indicate that ecDNA clusters amplify oncogenes and immune-modulating genes, helping tumors survive and evade immune responses. Promising therapies targeting ecDNA-induced stresses are in early trials, despite some clinical challenges. Mischel aims to transform cancer's genetic "loopholes" into therapeutic targets, improving precision oncology and patient outcomes. Read more: https://lnkd.in/eBN5cQjx #CancerResearch #ecDNA #Medicine #Oncology #GeneAmplification #CancerTherapy #Innovation #BiomedicalResearch

Prostate cancer still lacks a targeted national screening programme in the UK. Yesterday, Prostate Cancer Research (PCR) launched their report, “Prostate Cancer Screening: The Impact on the NHS,” highlighting how high-risk groups could benefit from early detection. Cambridge Clinical Laboratories (CCL), part of Source BioScience UK Ltd, supports this vision through providing validated biomarker tests such as Proclarix and Stockholm3, helping enhance risk stratification and reduce unnecessary MRI scans and biopsies, moving prostate cancer screening toward greater precision, efficiency and patient benefit. For more information on these tests, get in touch with us 👉 https://lnkd.in/e9T9g8i5 Prostate Cancer UK #ProstateCancer #Diagnostics #HealthcareQuality #Genomics #LifeScience

Researchers engineer a tool to dismantle cancer's RNA-built growth hubs. Researchers at Texas A&M Health Science Center have discovered how RNA builds “droplet hubs” in cancer cells and how to dismantle them. Their study focuses on translocation renal cell carcinoma (tRCC), an aggressive kidney cancer affecting mainly children and young adults. They found that RNA forms liquid-like condensates that promote cancer growth by activating tumor genes. To combat this, the team developed a nanobody-based molecular switch that dissolves these hubs, stopping tumor growth in lab cells and mouse models. This approach could offer new therapies for other pediatric and fusion-driven cancers by targeting condensate formation instead of individual genes, turning RNA from a messenger into a potential weakness in cancer’s machinery. Source: https://lnkd.in/dQ-wrS3i #CancerResearch #RNA #Oncology #NanobodyTherapy #PrecisionOncology #MolecularBiology

Calico Biosystems is committed to advancing breast cancer treatment by identifying the most effective therapeutic combinations. Check out our latest publication: https://lnkd.in/ectkqaJ9

🌸 October is Breast Cancer Awareness Month 🌸 In 2025, an estimated 316,950 new cases of invasive breast cancer will be diagnosed in women in the U.S At CancerTools.org (CancerToolsOrg), we’re proud to support cancer scientists worldwide. by providing access to a diverse range of innovative tools that advance breast cancer research, drug discovery, and precision oncology. Our not-for-profit biorepository breast cancer collection includes:  ☑ Anti-oestrogen resistant MCF7 and T47D derivative cell lines   ☑ Patient-derived organoid to model tumour complexity  ☑ A collection of 53 patient-derived xenograft (PDX) models, deposited by Prof. Alana Welm By making these resources available to cancer scientists worldwide, we aim to accelerate breakthroughs that drive breast cancer research, drug discovery, and precision oncology forward. 💡💗 Download our breast cancer poster here to explore our full collection: https://lnkd.in/eWGFe7bE #CancerResearch #CancerToolsOrg #CancerResearchUK #BreastCancerScience #TranslationalResearch #PrecisionOncology #DrugDiscovery #PreclinicalResearch #Organoids #PDXModels #CancerCellLines #OncologyInnovation #LifeSciences

🔍 How Are Molecular Technologies Reshaping Cancer Diagnostics? 🔬From early detection to personalized treatment selection, molecular technologies such as qPCR, targeted NGS, and whole-genome sequencing (WGS) are redefining what’s possible in precision oncology. 📄 Meridian’s latest white paper, "From Single Mutations to Whole Genomes: Molecular Technologies Shaping Precision Oncology Diagnostics", explores: ✅ A deep dive into the strengths and limitations of qPCR, tNGS, and WGS in cancer diagnostics ✅ How these technologies are applied in FDA-cleared and regulated oncology tests ✅ The expanding role of molecular diagnostics in guiding treatment and care in precision oncology 👉 Find our more, download our white paper now! https://hubs.la/Q03LXmDn0 #PrecisionOncology #CancerDiagnostics #qPCR #nextgensequencing #wholegenome #MolecularDiagnostics #LifeScience #biotech #POCT #pointofcare #oncology #oncologydiagnostics